Employees: 535
Size Zhejiang Wecome Pharmaceutical (300878.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $632M, the 3127th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥29.85 on 18 Nov 2026.
Performance Over six months the shares fell 17.5%, against -19.0% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 91.5% over the last twelve months (peer median +8.3%); the operating margin is -40.7% (peer median 9.2%).
Valuation It trades at 16.9× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 17).
Capital Return on invested capital runs 12.4 points below its cost of capital (7.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥252M | CN¥225M | CN¥349M | CN¥518M | CN¥531M |
| Revenue growth | — | -36% | -33% | -2% | — |
| Gross profit | CN¥144M | CN¥48.2M | CN¥96.4M | CN¥239M | CN¥293M |
| EBITDA | n/a | -CN¥61.4M | -CN¥94.8M | CN¥29.4M | CN¥79.7M |
| Net income | -CN¥127M | -CN¥227M | -CN¥147M | -CN¥8.95M | CN¥48.8M |
| Free cash flow | -CN¥57.8M | -CN¥81,740 | -CN¥147M | -CN¥81.0M | -CN¥28.2M |
| Capital expenditure | CN¥49.4M | CN¥67.2M | CN¥127M | CN¥139M | CN¥173M |
| Total debt | CN¥234M | CN¥171M | CN¥293M | CN¥453M | CN¥330M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300878.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.7% | -10.2% | 4th highest of 20 |
| 6-month return | -17.5% | -19.0% | 9th highest of 20 |
| Distance from 52-week high | -25.8% | -38.0% | 6th highest of 20 |
| Revenue growth (TTM) | +91.5% | +8.3% | 3rd highest of 17 |
| Operating margin | -40.7% | 9.2% | 2nd lowest of 16 |
| EV / Sales | 16.9× | 3.0× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -12.4 pp | -3.4 pp | 2nd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |